Sign up for upcoming conferences in the PROGRAMS section! | Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

Resources

Sep 23, 2025

Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration

Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration by: Michigan Medicine-University of Michigan Newswise —

Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration

Sep 16, 2025

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Recruiting- Phase 2 ClinicalTrials.gov IDNCT06635148 SponsorJanssen Research & Development, LLC Information Provided byJanssen Research & Development, LLC Clinical Trial Study

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Sep 16, 2025

FDA fast tracks SAR402663 intravitreal gene therapy for wet AMD

By:Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR402663 is a one-time intravitreal gene therapy designed to reduce

FDA fast tracks SAR402663 intravitreal gene therapy for wet AMD

Sep 12, 2025

Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report

Author(s): Martin David Harp Key Takeaways TearCare System’s inclusion in TFOS DEWS III report validates its clinical efficacy and role

Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report

Sep 9, 2025

A study of the progression of sensitivity loss in GA over time using inferred data

Author(s): Lynda Charters Key Takeaways Inferred sensitivity mapping predicts retinal function in GA with high spatial resolution, avoiding extensive psychophysical

A study of the progression of sensitivity loss in GA over time using inferred data

Sep 2, 2025

First patient dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111

By: Jordana Joy, Associate Editor The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients

First patient dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111

Sep 2, 2025

Inside genetics and glaucoma

August 28, 2025 By Kyra Dorgeloh, OD, FAAO Thomas A. Wong, OD, FAAO Glaucoma is a general term for a diverse

Inside genetics and glaucoma

Aug 26, 2025

VG801 receives regenerative medicine advanced therapy designation for Stargardt disease

By: Alex Young Fact checked by : Christine Klimanskis, ELS Key takeaways: VG801 is a dual-AAV gene therapy in development for

VG801 receives regenerative medicine advanced therapy designation for Stargardt disease

Aug 15, 2025

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Author(s): Lynda Charters Fact checked by: Karen S. DeLoss, OD, FAAO Key Takeaways Ocular exams can reveal cardiovascular health issues,

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Aug 12, 2025

Cosmetic procedures associated with serious ophthalmologic complications

Author(s): Lynda Charters Key Takeaways Minimally invasive cosmetic procedures can cause rare but severe ophthalmological complications, including irreversible vision loss

Cosmetic procedures associated with serious ophthalmologic complications

Aug 11, 2025

EyePoint completes enrollment in second phase 3 trial of sustained-release AMD therapy

ByJay S. Duker, MD ByAlex Young ByAnthony DeFino Fact checked by Christine Klimanskis, ELS Key takeaways: More than 400 patients

EyePoint completes enrollment in second phase 3 trial of sustained-release AMD therapy

Aug 11, 2025

This common fruit has over 1,600 compounds that boost brain, heart, and gut health

Published August 6, 2025 | Originally published on ScienceDaily Top Health A new article appearing in the current issue of the peer-reviewed Journal of

This common fruit has over 1,600 compounds that boost brain, heart, and gut health

Aug 6, 2025

Study supports Iluvien as ‘long-acting option’ in diabetic macular edema

Key takeaways: The NEW DAY study did not meet its primary endpoint but showed good outcomes in secondary endpoints. A

Study supports Iluvien as ‘long-acting option’ in diabetic macular edema

Aug 5, 2025

Geographic Atrophy Patient Experience Research

A new study is being conducted on geographic atrophy. They would like to hear about your experience with the drug

Geographic Atrophy Patient Experience Research

Jul 31, 2025

Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point

Author(s): Jordana Joy Key Takeaways LUMIFY Preservative Free eye drops are statistically non-inferior to LUMIFY in reducing ocular redness, with

Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point

Jul 28, 2025

VA-developed RainDrop Dispenser Aid aims to simplify use of single-use eye drops for patients with arthritis, tremors July 24, 2025

July 24, 2025 by Lynda Charters, Jordana Joy, Associate Editor Rain Eye Drops LLC announced the launch of a newly

VA-developed RainDrop Dispenser Aid aims to simplify use of single-use eye drops for patients with arthritis, tremors July 24, 2025

Jul 24, 2025

Novel AI-powered retina tracker detects eye disease in under one second

By: The Endocrine Society A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according

Novel AI-powered retina tracker detects eye disease in under one second

Jul 24, 2025

Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial

By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Danegaptide could be an oral therapy for patients with

Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial

Jul 24, 2025

Survey finds majority of US patients delaying eye care despite experiencing poor eyesight, eye health

By: Jordana Joy, Associate Editor Survey participants cited cost concerns, perceived inevitability, and deprioritization as obstacles to receiving eye care.

Survey finds majority of US patients delaying eye care despite experiencing poor eyesight, eye health

Jul 24, 2025

FDA fast tracks one-time intravitreal gene therapy for geographic atrophy

By: Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR446597 is designed to inhibit C1s and factor Bb

FDA fast tracks one-time intravitreal gene therapy for geographic atrophy

Jul 8, 2025

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Author(s): Martin David Harp Key Takeaways Alcon’s acquisition of LumiThera includes a PBM device for early and intermediate dry AMD,

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Jul 8, 2025

Can you eye doctor predict an impending stroke?

A university study shows certain types of retina problems are early signs of stroke. Research scientists from the University of

Can you eye doctor predict an impending stroke?

Jul 3, 2025

Happy Independence Day

    The Macular Degeneration Association would like to wish everyone a safe and excellent 4th of July. The offices

Happy Independence Day

Jun 30, 2025

36-month results from phase 1/2a clinical study of RG6501 released

Author(s): Kassi Filkins Key Takeaways RG6501 (OpRegen) cell therapy shows sustained visual acuity and retinal structure improvements in GA patients

36-month results from phase 1/2a clinical study of RG6501 released

Jun 30, 2025

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

Author(s): Glenn Yiu, MD, PhD Fact checked by: Sheryl Stevenson Frequent intravitreal injections for neovascular age-related macular degeneration present a

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

Jun 23, 2025

Instant coffee can cause blindness, says report

Published in Food Science & Nutrition, the study examined a large genetic dataset of more than 5,00,000 people and used

Instant coffee can cause blindness, says report

Jun 19, 2025

ILYX-002 rapidly improves immune-mediated dry eye disease in phase 2 trial

By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Dry eye disease associated with systemic autoimmune or inflammatory

ILYX-002 rapidly improves immune-mediated dry eye disease in phase 2 trial

Jun 16, 2025

Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT

Author(s): Christine Curcio, PhD, Sheryl Stevenson Conferences|International SPECTRALIS Symposium – and Beyond From basal laminar deposits to foveal centering, a

Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT

Jun 16, 2025

Cataract surgery may curb dementia, Alzheimer’s risk in those without anxiety, depression

By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Cataract surgery had a protective effect against overall dementia

Cataract surgery may curb dementia, Alzheimer’s risk in those without anxiety, depression

Jun 16, 2025

Undiagnosed AMD prevalence in urban setting higher than national average

By Alex Young Fact checked by Eamon N. Dreisbach Key takeaways: A hospital in New York had a higher percentage

Undiagnosed AMD prevalence in urban setting higher than national average

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.